Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
暂无分享，去创建一个
P. Galieni | M. Boccadoro | E. Zamagni | P. Musto | F. Pisani | E. Angelucci | P. Tosi | A. Ledda | A. Palumbo | A. Liberati | M. Offidani | O. Annibali | M. Cavo | R. Rizzi | S. Spada | A. Baraldi | M. Galli | S. Ronconi | N. Pescosta | M. Grasso | A. Cafro | A. Belotti | D. Vincelli | D. R. Scalabrini | P. Omede' | Chiara Cerrato | P. Omedè